» Articles » PMID: 38656394

Beta Hydroxybutyrate Induces Lung Cancer Cell Death, Mitochondrial Impairment and Oxidative Stress in a Long Term Glucose-restricted Condition

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2024 Apr 24
PMID 38656394
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metabolic plasticity gives cancer cells the ability to shift between signaling pathways to facilitate their growth and survival. This study investigates the role of glucose deprivation in the presence and absence of beta-hydroxybutyrate (BHB) in growth, death, oxidative stress and the stemness features of lung cancer cells.

Methods And Results: A549 cells were exposed to various glucose conditions, both with and without beta-hydroxybutyrate (BHB), to evaluate their effects on apoptosis, mitochondrial membrane potential, reactive oxygen species (ROS) levels using flow cytometry, and the expression of CD133, CD44, SOX-9, and β-Catenin through Quantitative PCR. The activity of superoxide dismutase, glutathione peroxidase, and malondialdehyde was assessed using colorimetric assays. Treatment with therapeutic doses of BHB triggered apoptosis in A549 cells, particularly in cells adapted to glucose deprivation. The elevated ROS levels, combined with reduced levels of SOD and GPx, indicate that oxidative stress contributes to the cell arrest induced by BHB. Notably, BHB treatment under glucose-restricted conditions notably decreased CD133 expression, suggesting a potential inhibition of cell survival through the downregulation of CD133 levels. Additionally, the simultaneous decrease in mitochondrial membrane potential and increase in ROS levels indicate the potential for creating oxidative stress conditions to impede tumor cell growth in such environmental settings.

Conclusion: The induced cell death, oxidative stress and mitochondria impairment beside attenuated levels of cancer stem cell markers following BHB administration emphasize on the distinctive role of metabolic plasticity of cancer cells and propose possible therapeutic approaches to control cancer cell growth through metabolic fuels.

Citing Articles

Exploring the potential of gemcitabine-metal-organic frameworks in combating pancreatic cancer under ketogenic conditions.

Nekoufar S, Ghorbani M, Safaei S, Khosroushahi G, Shirian F, Baradaran B BMC Cancer. 2025; 25(1):53.

PMID: 39789481 PMC: 11720622. DOI: 10.1186/s12885-024-13397-x.


Therapeutic potential of β-hydroxybutyrate in the management of pancreatic neoplasms: exploring novel diagnostic and treatment strategies.

Vaezi M, Nekoufar S, Robati A, Salimi V, Tavakoli-Yaraki M Lipids Health Dis. 2024; 23(1):376.

PMID: 39543582 PMC: 11562866. DOI: 10.1186/s12944-024-02368-7.


Assessment of the circulating levels of immune system checkpoint selected biomarkers in patients with lung cancer.

Safizadeh B, Sadeh M, Robati A, Riahi T, Tavakoli-Yaraki M Mol Biol Rep. 2024; 51(1):1036.

PMID: 39361074 DOI: 10.1007/s11033-024-09971-y.

References
1.
Buijs A, Poot M, van der Crabben S, Van Der Zwaag B, van Binsbergen E, van Roosmalen M . Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees. Leukemia. 2012; 26(9):2151-4. DOI: 10.1038/leu.2012.79. View

2.
de Sousa V, Carvalho L . Heterogeneity in Lung Cancer. Pathobiology. 2018; 85(1-2):96-107. DOI: 10.1159/000487440. View

3.
Anastasiou D . Tumour microenvironment factors shaping the cancer metabolism landscape. Br J Cancer. 2016; 116(3):277-286. PMC: 5294476. DOI: 10.1038/bjc.2016.412. View

4.
Schwartz L, Supuran C, Alfarouk K . The Warburg Effect and the Hallmarks of Cancer. Anticancer Agents Med Chem. 2016; 17(2):164-170. DOI: 10.2174/1871520616666161031143301. View

5.
Ortega A, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva J . Glucose avidity of carcinomas. Cancer Lett. 2008; 276(2):125-35. DOI: 10.1016/j.canlet.2008.08.007. View